Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower.
Immunovant Inc. (IMVT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Seas Capital Sina Toussi | 4,612,692 | $155,816,736 | +47% | 1.8% |
| 2. | Bayforest Capital Theodoros Tsagaris | 97 | $3,277 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.00 | 16,666,666 | $349,999,986.00 | 113,317,007 | 2025-12-12 | Filing | |
| $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | 2025-01-13 | Filing | |
| $38.00 | 1,526,316 | $58,000,008.00 | 79,805,331 | 2023-10-02 | Filing | |
| $6.00 | 416,667 | $2,500,002.00 | 73,805,331 | 2022-10-06 | Filing | |
| $5.60 | 15,000 | $84,000.00 | 20,000 | 2022-09-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.50 | 6,606 | $188,271.00 | 234,192 | 2026-10-28 | Filing | |
| $28.94 | 2,595 | $75,099.30 | 198,937 | 2026-10-21 | Filing | |
| $32.06 | 1,596 | $51,167.76 | 201,532 | 2026-10-07 | Filing | |
| $32.06 | 2,213 | $70,948.78 | 203,128 | 2026-10-07 | Filing | |
| $32.06 | 1,327 | $42,543.62 | 175,218 | 2026-10-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 359,081 | $12,129,756 | 0.01% | |
| 2. | 124,782 | $4,215,136 | 0.12% | |
| 3. | 65,666 | $2,218,184 | 0% | |
| 4. | 46,791 | $1,580,600 | 0.01% | |
| 5. | 46,100 | $1,557,258 | 0.01% |
News See All
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to invest in. On May 21, H.C. Wainwright boosted Immunovant, Inc.
13 Best Short Squeeze Stocks to Invest In
In this article, we will take a look at the 13 Best Short Squeeze Stocks to Invest In.
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
Immunovant, Inc. (NASDAQ:IMVT) is one of the best momentum stocks to buy according to analysts. Truist lifted the price target on Immunovant, Inc.
10 Best Momentum Stocks to Buy According to Analysts
In this article, we will look at the 10 Best Momentum Stocks to Buy According to Analysts.
Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial
Immunovant Inc. (NASDAQ:IMVT) is one of the 10 Stocks With Insane Returns Right Now.
10 Stocks With Insane Returns Right Now
Ten stocks soared higher on Wednesday, mirroring a robust broader market performance, as investors took heart from a flurry of company-specific developments.
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update
Immunovant, Inc. (NASDAQ:IMVT) ranks among the most shorted stocks to buy according to analysts. On February 6, Immunovant, Inc.
11 Most Shorted Stocks to Buy According to Analysts
In this article, we will take a look at the 11 Most Shorted Stocks to Buy According to Analysts.
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript February 6, 2026Immunovant, Inc. beats earnings expectations. Reported EPS is $-0.60951, expectations were $-0.72.
Hedge Fund Resource Center